Such a tracer could cover the whole spectrum of the disease by targeting GRPR which is highly overexpressed in the early stages and PSMA that is predominantly overexpressed in the late, androgen independent, stages of the disease, thus potentially increasing the sensitivity towards detecting prostate cancer and its distant metastases. This evidence concerns the gene FOLH1 and prostate cancer.